CLDX Celldex Corp: רווח נקי למניה ב-12 החודשים האחרונים

Celldex Therapeutics (CLDX) is accelerating the rollout of cancer drugs through partnerships with medical centers. The history of net income per share growth YoY ttm visualizes the dynamics of this process, where -27.20 shows the current value of the metric. The company is developing unique antibodies against urticaria while effectively utilizing external outsourcing to conduct early-stage clinical trials.
Celldex - פילוחים אנליטיים ומדדי מפתח (CLDX)

The YoY TTM net income per share growth trend reflects the efficiency of Celldex Therapeutics (CLDX) in developing monoclonal antibodies, converting clinical trial successes into shareholder value. This indicator measures the percentage change in trailing twelve-month EPS, allowing investors to assess business scaling rates and timely identify the risk of overpaying for the asset during extreme earnings peaks.